Aid cuts threaten global rollout of long-acting HIV prevention drug, experts warn
Experts at AIDS 2026 say lenacapavir, a long-acting injectable PrEP, could dramatically cut new HIV infections if scaled up, but funding cuts to USAID are hampering access, threatening outreach, affordability, and the ability to reach high-need populations worldwide.